NEW EQA FOR 2027



Advancing Quality in Molecular Haemato-Oncology Testing

Designed for laboratories delivering molecular diagnostics in haemato-oncology, these new EQA schemes provide an **end-to-end assessment of testing performance**, evaluating not only **variant detection**, but also **clinical interpretation and reporting.**

New Pilot Schemes

- **Myeloproliferative Neoplasms (MPN)** **Product code:** 09-MPN-27

Assessment of *JAK2, CALR* and *MPL* variant detection, interpretation and reporting using clinically relevant MPN cases.

- **Acute Myeloid Leukaemia (AML)** **Product code:** 09-AML-27

Assessment of *FLT3-ITD, FLT3-TKD, IDH1* and *NPM1* variant detection, interpretation and reporting using clinically relevant AML cases.

- **Myeloid Neoplasms Gene Panel Testing** **Product code:** 09-MYP-27

Assessment of variant detection, interpretation and reporting for laboratories that routinely use a myeloid specific NGS gene panel testing workflow.

Why participate?

Real-world assessment

- DNA samples with clinically realistic referral information.
- Assessment of variant detection and interpretation
- Evaluation of clinical reporting
- Real-world testing scenarios
- Annual scheme distributions

Benefits for your laboratory

- Assess analytical performance and clinical interpretation
- Evaluate your complete testing workflow
- Demonstrate quality, consistency and confidence
- Benchmark against peer laboratories
- Use clinically relevant cases that reflect routine practice

The Complete Testing Pathway. Assessed.

Register your interest

EMQN CIC, Third Floor, ICE Building, 3 Exchange Quay Salford, M5 3ED

www.emqn.org office@emqn.org +44 (0) 161 757 1591 EMQN

emqn

Copyright EMQN CIC. No part of this document may be copied, distributed or published in any form without the permission of the EMQN CIC V.1